Gibson Dunn & Crutcher advised Esperion Therapeutics, Inc. on the deal.Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced that it has entered into a Royalty Purchase Agreement (the…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
